- Elekta’s net sales for the fourth quarter reached SEK5.16 billion, slightly below the estimated SEK5.18 billion.
- The company’s adjusted operating profit for the same period was SEK843 million.
- The board has proposed a dividend per share of SEK2.40, slightly above the estimated SEK2.38.
- Analyst ratings for the company include 6 buys, 6 holds, and 7 sells.
“`
A look at Elekta AB Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Elekta AB, a company specializing in advanced medical products for neurological disorders and cancer treatment, has garnered positive scores in key areas according to Smartkarma Smart Scores. With a strong focus on delivering value to investors and offering an attractive dividend, Elekta is positioned well in the market. Additionally, the company shows promising growth potential alongside a resilient performance, indicating a stable foundation for long-term success. However, the momentum score of Elekta suggests potential areas for improvement in terms of market traction and investor interest.
Elekta AB‘s innovative products such as the Gamma Knife for non-invasive surgery and systems for neurosurgery have contributed to its global presence and market reach. With high scores in value and dividends, Elekta demonstrates a commitment to rewarding investors while maintaining growth opportunities and resilience in the face of challenges. While the momentum score may indicate room for enhancement, Elekta’s overall outlook remains positive, showcasing a company with solid fundamentals and potential for strategic development in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars
